End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.28 CNY | -0.17% | -1.32% | +23.22% |
May. 28 | Nanjing Pharmaceutical Issues 500 Million Yuan Ultra-Short-Term Bonds | MT |
May. 24 | Vanke Obtains 20 Billion Yuan Through Syndicated Lending Facility | MT |
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Its low valuation, with P/E ratio at 5.82 and 5.39 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.22% | 118B | B- | ||
+19.12% | 582B | C+ | ||
+18.87% | 313B | C+ | ||
+15.71% | 251B | C+ | ||
+21.74% | 209B | C | ||
+19.14% | 180B | B- | ||
+24.16% | 169B | B- | ||
+9.58% | 164B | C+ | ||
+11.18% | 154B | B- | ||
-10.40% | 140B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600036 Stock
- Ratings China Merchants Bank Co., Ltd.